Regulatory source record

FDA & DEA Kratom Timeline: 7-OH Actions

Federal actions differ by compound and product. A warning, a proposed threshold, and an effective scheduling order have different consequences; the dated source controls.

By Kratom Finder Editorial · Updated . Source-based editorial update; no new clinician review is claimed.

Editorial illustration of a sequence of archival file folders arranged on a desk beside a blank open notebook and a botanical leaf.

August 26, 2026: three related compounds scheduled

DEA issued a temporary Schedule I order for mitragynine pseudoindoxyl, MGM-15, and MGM-16. The order identifies the covered substances and takes effect August 26, 2026. It is distinct from the separate proceeding about a threshold for 7-OH.

August 26, 2026: 7-OH threshold comments extended

HHS extended the comment period on the proposed 7-OH threshold. An extension or a notice of intent is not itself a final scheduling order. Check the applicable Federal Register proceeding for subsequent orders and effective dates.

July 1, 2026: DEA announces intent to schedule

DEA announced two notices: one concerning 7-OH above a specified threshold and another covering three related substances. The announcement explains that controls take effect through scheduling orders, not simply through the announcement.

December 2, 2025: seizure of 7-OH products

FDA announced that the U.S. Marshals Service seized approximately 73,000 units of 7-OH products from three Missouri firms, in coordination with the Department of Justice. This is a specific enforcement event, not a statement about every product sold as kratom.

July 29, 2025: FDA recommends scheduling action

FDA recommended controlling certain 7-OH products and described the next steps involving DEA. The announcement focused on concentrated 7-OH products. That scope does not establish that leaf products meet federal requirements for foods, supplements, or medical claims.

July 15, 2025: warning-letter announcement

FDA announced warning letters to seven firms marketing products containing 7-OH. A warning letter identifies the agency’s stated violations; it is not product approval or a clinical comparison between brands.

How to use this timeline

This is a selected chronology of verified agency documents, checked September 8, 2026. Each source must be read for its scope. State and local requirements are separate, and later regulatory changes may supersede an earlier notice.

Sources

Sources support the stated facts; they do not validate an individual product or replace personal medical care. Report a correction.

Related information

Safety overview · All articles · State rules · Store directory